Ocular delivery of felodipine for the management of intraocular pressure and inflammation: Effect of film plasticizer and in vitro in vivo evaluation

Int J Pharm. 2023 Jul 25:642:123153. doi: 10.1016/j.ijpharm.2023.123153. Epub 2023 Jun 18.

Abstract

Glaucoma may cause irreversible eyesight loss and damage to the optic nerve. Trabecular meshwork obstruction may raise intraocular pressure (IOP) in open-angle and/or closed-angle type inflammatory glaucoma. Ocular delivery of felodipine (FEL) has been undertaken for the management of intraocular pressure and inflammation. FEL film was formulated using different plasticizers, and IOP has been assessed using a normotensive rabbit eye model. Ocular acute inflammation induced by carrageenan has also been monitored. Drug release has been enhanced significantly (93.9 % in 7 h) in the presence of DMSO (FDM) as a plasticizer in the film compared to others (59.8 to 86.2 % in 7 h). The same film also exhibited the highest ocular permeation of 75.5 % rather than others (50.5 to 61.0 %) in 7 h. Decreased IOP was maintained up to 8 h after ocular application of FDM compared to the solution of FEL only up to 5 h. Ocular inflammation has almost been disappeared within 2 h of using the film (FDM), whereas inflammation has been continued even after 3 h of the induced rabbit without film. DMSO plasticized felodipine film could be used for the better management of IOP and associated inflammation.

Keywords: Glaucoma; In vitro in vivo correlation; Inflammation; Intraocular pressure; Ocular delivery.

MeSH terms

  • Animals
  • Dimethyl Sulfoxide
  • Felodipine
  • Glaucoma* / drug therapy
  • Intraocular Pressure*
  • Plasticizers
  • Rabbits
  • Trabecular Meshwork

Substances

  • Plasticizers
  • Felodipine
  • Dimethyl Sulfoxide